ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Outcomes Following Transplantation for Hepatocellular Carcinoma.

P. Tabrizian, K. Nakazawa, J. Prigoff, M. Schwartz, S. Florman.

Transplant, Recanati/Miller Transplantation Institute, New York, Ny

Meeting: 2017 American Transplant Congress

Abstract number: A84

Keywords: Hepatocellular carcinoma, Liver transplantation, Recurrence, Survival

Session Information

Date: Saturday, April 29, 2017

Session Name: Poster Session A: Clinical Science: Liver - Hepatocellular Carcinoma and Cholangiocarcinoma Malignancies

Session Time: 5:30pm-7:30pm

 Presentation Time: 5:30pm-7:30pm

Location: Hall D1

Related Abstracts
  • Recurrence of Hepatocellular Carcinoma After Transarterial Chemoembolization (TACE) Alone and TACE in Combination With Other Treatment Modalities
  • Pretransplant Elevated Plasma Fibrinogen Level Is Associated With Tumor Recurrence and Poor Prognosis in Hepatocellular Carcinoma Patients After Liver Transplantation

Objectives: To examine the prognostic features and outcomes of patients undergoing transplantation for hepatocellular carcinoma (HCC).

Methods: A single-institution retrospective chart review was performed on all patients who underwent transplantation (OLT) for HCC between 1990-2014. Clinical data were abstracted and statistical analyses were conducted in standard fashion.

Results: 716 patients underwent OLT for HCC, of which 117 patients developed recurrence. The median follow up of survivors was 59.8 (1.2-166) months. Recurrences were frequently intrahepatic (42%), associated with multiple tumors (58%) and occurred during the first two years after OLT (64%). Overall, the 5-year recurrence rate after OLT was 17%. Factors associated with recurrence after OLT were age > 50 years (p=0.001), multinodularity and tumor > 3 cm at diagnosis (p<0.001), AFP > 400 ng/ml at diagnosis (p=0.004), number of locoregional therapies (>1) prior to OLT (p=0.01), ineffectiveness of treatment (p=0.006), tumors outside Milan criteria (0.002), grade of tumor (poor) (p<0,001), vascular invasion (<0.001), and tumor viability (>3 cm) on pathology (p<0.001). Overall, the 5-year survival rate after OLT was 70%. Factors associated with poor survival were diameter of viable tumor on pathology > 3 cm (p=0.031), vascular invasion (0.001), extrahepatic recurrence (p<0.001), time to recurrence <2 years (p=0.001), and treatment of recurrence (p<0.001). Repeat resection was offered in 40% of patients.

Conclusion: Recurrence can be expected to occur in 17% at 5 years. Predictors of survival and recurrence after OLT are multifactorial. In patients with recurrence, the optimal treatment will predict outcome.

CITATION INFORMATION: Tabrizian P, Nakazawa K, Prigoff J, Schwartz M, Florman S. Outcomes Following Transplantation for Hepatocellular Carcinoma. Am J Transplant. 2017;17 (suppl 3).

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Tabrizian P, Nakazawa K, Prigoff J, Schwartz M, Florman S. Outcomes Following Transplantation for Hepatocellular Carcinoma. [abstract]. Am J Transplant. 2017; 17 (suppl 3). https://atcmeetingabstracts.com/abstract/outcomes-following-transplantation-for-hepatocellular-carcinoma/. Accessed April 15, 2021.

« Back to 2017 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
      • Direct Oral Anticoagulation Use in Kidney Transplant Recipients

      Visit Our Partner Sites

      American Transplant Congress (ATC)

      Visit the official site for the American Transplant Congress »

      American Journal of Transplantation

      The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

      American Society of Transplantation (AST)

      An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

      American Society of Transplant Surgeons (ASTS)

      The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

      Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

      Privacy Policy | Terms of Use

      loading Cancel
      Post was not sent - check your email addresses!
      Email check failed, please try again
      Sorry, your blog cannot share posts by email.
      This site uses cookies: Find out more.